DYN Dyne Therapeutics Inc

$DYN now in here. the sept 8 dump came from novartis missing the primary endpoint in harbor, a dm1 trial. fair point, dyne’s dm1 program uses the same delivery idea and the same vhot endpoint, so that read-across stays open until achieve topline in q1 2027. but the jan 21 pdufa is a different drug in a different disease: z-rostudirsen, exon 51 dmd, priority review. deliver showed 5.46% muscle-adjusted dystrophin, 2.87% unadjusted, p<0.0001, functional data nominal on 24 vs 8. exondys 51, approved for the same patients, shows 0.93% on its label. cash 898.5m at june 30 plus about 405m net from july, runway guided into q2 2028. risk i’d put first: fda’s view on dystrophin as a surrogate after sarepta’s confirmatory misses. wms sept 30 next. not advice.

$DYN would be a sweet last entry if the data tomorrow would be positiv. If not deeper levels ahead. Trying to see it positiv.

$DYN Let's not forget that DM1 is progressive. Success can sometimes matter dramatically with simple stabilization. $DYN appears to have gone a step further. We're apparently getting actual functional improvement at one year, while matched natural-history patients deteriorate. That is considerably better than a story consisting solely of biomarker improvement. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

$DYN This guy gets it. Massive overreaction recently allowed a significant biying opportunity. Several thesis confirming and derisking catalysts on the horizon, starting with new 12-month ACHIEVE/DYNE-101 DM1 data at WMS. Do your research and I think you'll realize we found a tremendous opportunity with $DYN at this time. Follow/Subscribe for more suggestions/perspective. Would love to jear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

$DYN Dyne Therapeutics Is Maintained at Buy by Chardan Capitalabout this security Dow Jones Newswires : 09/30/2026 07:10 AM EST ViewDyne Therapeutics Price Target Maintained With a $38.00/Share byabout this security Dow Jones Newswires : 09/30/2026 07:10 AM EST